

---

David Fineberg, MD, MBA has more than 20 years of experience in the pharmaceutical industry, primarily in clinical development, and also with extensive experience in regulatory affairs, pharmacovigilance, and quality systems.

With extensive expertise spanning various phases of clinical development, Dr. Fineberg has worked across diverse therapeutic areas, including plasma derived products, hematology, immunology, neurology, sepsis, oncology, and immuno-oncology (cell therapy). His experience extends to medical monitoring in 25 countries, leading interactions with the FDA during formal meetings for multiple indications and managing and all aspects of clinical operations and development.

Dr. Fineberg has an impressive career history. He spent 12 years at Grifols (formerly Bayer, Talecris) followed by 7 years with the Asahi Kasei Group. Most recently he served as Chief Medical Officer for Mirror Biologics.

His educational path includes undergraduate training at Syracuse University, medical studies at the Sackler School of Medicine at Tel Aviv University, residency in general surgery at the University at Buffalo, and a fellowship in plastic and reconstructive surgery at the Albert Einstein College of Medicine. Additionally, he obtained his Global Executive MBA from the UNC Kenan-Flagler Business School at the University of North Carolina at Chapel Hill.